MCID: HRT007
MIFTS: 47

Heart Cancer

Categories: Cancer diseases, Cardiovascular diseases

Aliases & Classifications for Heart Cancer

MalaCards integrated aliases for Heart Cancer:

Name: Heart Cancer 12 15
Malignant Neoplasm of Heart 12 74
Heart Neoplasm 17 74
Malignant Cardiac Tumor 12
Cardiac Carcinoma 74
Tumour of Heart 12
Heart Neoplasms 45
Cardiac Tumor 12

Classifications:



External Ids:

Disease Ontology 12 DOID:117
ICD9CM 36 164.1
MeSH 45 D006338
NCIt 51 C3081 C3548
SNOMED-CT 69 93825008
ICD10 34 C38.0

Summaries for Heart Cancer

Disease Ontology : 12 A cardiovascular cancer located in the heart.

MalaCards based summary : Heart Cancer, also known as malignant neoplasm of heart, is related to tuberous sclerosis 1 and heart tumor, and has symptoms including heart problem An important gene associated with Heart Cancer is PTH1R (Parathyroid Hormone 1 Receptor), and among its related pathways/superpathways are Constitutive Signaling by AKT1 E17K in Cancer and TP53 Regulates Metabolic Genes. The drugs Bevacizumab and leucovorin have been mentioned in the context of this disorder. Affiliated tissues include heart, lung and kidney, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Wikipedia : 77 Heart cancer is an extremely rare form of cancer that is divided into primary tumors of the heart and... more...

Related Diseases for Heart Cancer

Diseases related to Heart Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 106, show less)
# Related Disease Score Top Affiliating Genes
1 tuberous sclerosis 1 29.3 MTOR TSC2
2 heart tumor 11.0
3 primary pediatric heart tumor 11.0
4 primary adult heart tumor 11.0
5 myxoma, intracardiac 10.9
6 pericardium cancer 10.1
7 posterior mediastinum cancer 10.1
8 pleural cancer 10.1
9 mediastinal cancer 10.1
10 hepatic angiomyolipoma 10.1 MTOR TSC2
11 angiomyolipoma 10.1 MTOR TSC2
12 kidney angiomyolipoma 10.1 MTOR TSC2
13 subependymal glioma 10.1 MTOR TSC2
14 benign ependymoma 10.1 MTOR TSC2
15 polycystic liver disease 1 with or without kidney cysts 10.1 MUC16 TSC2
16 kidney benign neoplasm 10.1 MTOR TSC2
17 subependymal giant cell astrocytoma 10.0 MTOR TSC2
18 central nervous system benign neoplasm 10.0 MTOR TSC2
19 kaposiform hemangioendothelioma 10.0 MTOR PECAM1
20 focal cortical dysplasia, type ii 10.0 MTOR TSC2
21 chondroma 10.0 PTH1R SDHB
22 tuberous sclerosis 2 10.0 MTOR TSC2
23 tuberous sclerosis 10.0
24 lymphangioleiomyomatosis 9.9 MTOR TSC2
25 pericardial mesothelioma 9.9 ERF MUC16
26 von hippel-lindau syndrome 9.9 SDHB TSC2
27 polycystic kidney disease 1 with or without polycystic liver disease 9.9 MTOR TSC2
28 hemangioma 9.8
29 lymphoma 9.8
30 myocardial infarction 9.8
31 fibroma 9.8
32 heart disease 9.8
33 autosomal genetic disease 9.8 SDHB TSC2
34 basal cell nevus syndrome 9.7
35 basal cell carcinoma 1 9.7
36 angiosarcoma 9.7
37 malignant fibroxanthoma 9.7
38 basal cell carcinoma 9.7
39 histiocytoma 9.7
40 fibrous histiocytoma 9.7
41 coronary artery aneurysm 9.7
42 undifferentiated pleomorphic sarcoma 9.7
43 renal cell carcinoma, nonpapillary 9.6 MTOR SDHB TSC2
44 renal cell carcinoma, papillary, 1 9.6 MTOR SDHB
45 wilms tumor 5 9.6
46 wilms tumor 6 9.6
47 hydronephrosis 9.6
48 cerebrovascular disease 9.6
49 hyperthyroidism 9.6
50 hypoxia 9.6
51 apnea, obstructive sleep 9.5
52 atrial standstill 1 9.5
53 progressive familial heart block, type ia 9.5
54 cardiac conduction defect 9.5
55 down syndrome 9.5
56 wolff-parkinson-white syndrome 9.5
57 budd-chiari syndrome 9.5
58 orthostatic intolerance 9.5
59 carney complex variant 9.5
60 lymphatic malformation 7 9.5
61 acute myocardial infarction 9.5
62 heart valve disease 9.5
63 lymphoblastic lymphoma 9.5
64 paraganglioma 9.5
65 sleep apnea 9.5
66 adenoid cystic carcinoma 9.5
67 left bundle branch hemiblock 9.5
68 endocarditis 9.5
69 sarcoma 9.5
70 hemopericardium 9.5
71 cardiac tamponade 9.5
72 pericardial effusion 9.5
73 patulous eustachian tube 9.5
74 bronchus cancer 9.5
75 patent foramen ovale 9.5
76 squamous cell papilloma 9.5
77 echinococcosis 9.5
78 squamous cell carcinoma 9.5
79 pericarditis 9.5
80 atrial heart septal defect 9.5
81 leiomyosarcoma 9.5
82 papilloma 9.5
83 mesenchymoma 9.5
84 capillary hemangioma 9.5
85 cervix carcinoma 9.5
86 antiphospholipid syndrome 9.5
87 myxosarcoma 9.5
88 spindle cell sarcoma 9.5
89 erdheim-chester disease 9.5
90 perineurioma 9.5
91 cavernous hemangioma 9.5
92 leiomyomatosis 9.5
93 heart sarcoma 9.5
94 intravenous leiomyomatosis 9.5
95 malignant mesenchymoma 9.5
96 acquired immunodeficiency syndrome 9.5
97 polyhydramnios 9.5
98 pulmonary embolism 9.5
99 rere-related disorders 9.5
100 aneurysm of sinus of valsalva 9.5
101 bidirectional tachycardia 9.5
102 bronchogenic cyst 9.5
103 fetal edema 9.5
104 hydrops fetalis 9.5
105 lipogranulomatosis 9.5
106 pure autonomic failure 9.5

Graphical network of the top 20 diseases related to Heart Cancer:



Diseases related to Heart Cancer

Symptoms & Phenotypes for Heart Cancer

UMLS symptoms related to Heart Cancer:


heart problem

GenomeRNAi Phenotypes related to Heart Cancer according to GeneCards Suite gene sharing:

27 (showing 22, show less)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-102 9.72 ERF PECAM1 TSC2
2 Increased shRNA abundance (Z-score > 2) GR00366-A-105 9.72 ERF PECAM1
3 Increased shRNA abundance (Z-score > 2) GR00366-A-107 9.72 ERF
4 Increased shRNA abundance (Z-score > 2) GR00366-A-123 9.72 PECAM1
5 Increased shRNA abundance (Z-score > 2) GR00366-A-127 9.72 TSC2
6 Increased shRNA abundance (Z-score > 2) GR00366-A-13 9.72 PECAM1
7 Increased shRNA abundance (Z-score > 2) GR00366-A-132 9.72 TSC2
8 Increased shRNA abundance (Z-score > 2) GR00366-A-140 9.72 PECAM1
9 Increased shRNA abundance (Z-score > 2) GR00366-A-146 9.72 ERF
10 Increased shRNA abundance (Z-score > 2) GR00366-A-166 9.72 TSC2
11 Increased shRNA abundance (Z-score > 2) GR00366-A-198 9.72 PECAM1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-2 9.72 PECAM1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-207 9.72 TSC2
14 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.72 PECAM1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-32 9.72 ERF
16 Increased shRNA abundance (Z-score > 2) GR00366-A-42 9.72 PECAM1
17 Increased shRNA abundance (Z-score > 2) GR00366-A-49 9.72 ERF
18 Increased shRNA abundance (Z-score > 2) GR00366-A-52 9.72 PECAM1
19 Increased shRNA abundance (Z-score > 2) GR00366-A-56 9.72 PECAM1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-73 9.72 ERF
21 Increased shRNA abundance (Z-score > 2) GR00366-A-82 9.72 ERF
22 Increased shRNA abundance (Z-score > 2) GR00366-A-92 9.72 TSC2

MGI Mouse Phenotypes related to Heart Cancer:

47 (showing 6, show less)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.85 APOE ERF MTOR PECAM1 PTH1R TSC2
2 hematopoietic system MP:0005397 9.8 APOE ERF MTOR PECAM1 PTH1R SDHB
3 endocrine/exocrine gland MP:0005379 9.72 APOE MTOR PTH1R SDHB TSC2
4 homeostasis/metabolism MP:0005376 9.7 APOE ERF MTOR PECAM1 PTH1R SDHB
5 renal/urinary system MP:0005367 9.35 APOE MTOR PECAM1 SDHB TSC2
6 skeleton MP:0005390 9.02 APOE ERF MTOR PECAM1 PTH1R

Drugs & Therapeutics for Heart Cancer

Drugs for Heart Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 186, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 3 216974-75-3
2
leucovorin Approved Phase 3,Phase 2,Phase 1,Not Applicable 58-05-9 143 6006
3
Fluorouracil Approved Phase 3 51-21-8 3385
4
Levoleucovorin Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 68538-85-2
5
Irinotecan Approved, Investigational Phase 3,Phase 2 100286-90-6, 97682-44-5 60838
6
Oxaliplatin Approved, Investigational Phase 3 61825-94-3 43805 6857599 5310940 9887054
7
Cetuximab Approved Phase 3 205923-56-4 56842117 2333
8
Prednisolone Approved, Vet_approved Phase 3,Phase 2 50-24-8 5755
9
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Not Applicable 50-18-0, 6055-19-2 2907
10
Prednisone Approved, Vet_approved Phase 3,Phase 2 53-03-2 5865
11
Mercaptopurine Approved Phase 3,Phase 2,Not Applicable 50-44-2 667490
12
Cytarabine Approved, Experimental, Investigational Phase 3,Phase 2,Not Applicable 147-94-4, 65-46-3 6253
13
Thioguanine Approved Phase 3 154-42-7 2723601
14
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Not Applicable 50-02-2 5743
15
Methylprednisolone hemisuccinate Approved Phase 3,Phase 2 2921-57-5
16
Vincristine Approved, Investigational Phase 3,Phase 2,Not Applicable 2068-78-2, 57-22-7 5978
17
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
18
Prednisolone phosphate Approved, Vet_approved Phase 3,Phase 2 302-25-0
19
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3,Not Applicable 1177-87-3
20
Methotrexate Approved Phase 3,Phase 2,Phase 1,Not Applicable 1959-05-2, 59-05-2 126941
21
Daunorubicin Approved Phase 3,Phase 2,Not Applicable 20830-81-3 30323
22
Methylprednisolone Approved, Vet_approved Phase 3,Phase 2 83-43-2 6741
23
Etoposide Approved Phase 3,Phase 2,Phase 1,Not Applicable 33419-42-0 36462
24
Mesna Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 3375-50-6 598
25
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 135968-09-1
26
Sargramostim Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 123774-72-1, 83869-56-1
27
Carboplatin Approved Phase 3,Phase 2 41575-94-4 10339178 38904 498142
28
Lomustine Approved, Investigational Phase 3,Phase 2 13010-47-4 3950
29
rituximab Approved Phase 3,Phase 2 174722-31-7 10201696
30
Mitoxantrone Approved, Investigational Phase 3,Phase 2 65271-80-9 4212
31
Mechlorethamine Approved, Investigational Phase 3,Phase 2,Phase 1 51-75-2 4033
32
Ifosfamide Approved Phase 3,Phase 2,Phase 1 3778-73-2 3690
33
Dactinomycin Approved, Investigational Phase 3,Phase 2 50-76-0 457193 2019
34
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
35
Cisplatin Approved Phase 3,Phase 1,Not Applicable 15663-27-1 2767 441203 84093
36
Fulvestrant Approved, Investigational Phase 3 129453-61-8 17756771 104741
37
Anastrozole Approved, Investigational Phase 3 120511-73-1 2187
38
Pegaspargase Approved, Investigational Phase 3,Not Applicable 130167-69-0
39
Vinblastine Approved Phase 3,Phase 2 865-21-4 241903 13342
40
Epirubicin Approved Phase 3 56420-45-2 41867
41
Procarbazine Approved, Investigational Phase 3 671-16-9 4915
42
Trioxsalen Approved Phase 3 3902-71-4 5585
43
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
44
Pemetrexed Approved, Investigational Phase 3 150399-23-8, 137281-23-3 60843 446556
45
Selenium Approved, Investigational, Vet_approved Phase 3 7782-49-2
46
Iodine Approved, Investigational Phase 3 7553-56-2 807
47
Vidarabine Approved, Investigational Phase 3 24356-66-9 21704 32326
48
Fludarabine Approved Phase 3 75607-67-9, 21679-14-1 30751
49
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 59-30-3 6037
50
Calcium Approved, Nutraceutical Phase 3,Phase 2,Phase 1,Not Applicable 7440-70-2 271
51
Prednisolone hemisuccinate Experimental Phase 3,Phase 2 2920-86-7
52
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
53
Camptothecin Experimental Phase 3 7689-03-4
54
Atrasentan Investigational Phase 3 173937-91-2, 195733-43-8 159594
55 topoisomerase I inhibitors Phase 3,Phase 2,Phase 1
56 Trace Elements Phase 3,Phase 1,Not Applicable
57 Nutrients Phase 3,Phase 1,Not Applicable
58 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1,Not Applicable
59 Angiogenesis Modulating Agents Phase 3
60 Vitamin B9 Phase 3,Phase 2,Phase 1,Not Applicable
61 Immunologic Factors Phase 3,Phase 2,Phase 1,Not Applicable
62 Antidotes Phase 3,Phase 2,Phase 1,Not Applicable
63 Vitamin B Complex Phase 3,Phase 2,Phase 1,Not Applicable
64 Antimetabolites Phase 3,Phase 2,Phase 1,Not Applicable
65 Cola Phase 3
66 Angiogenesis Inhibitors Phase 3,Phase 2
67 Protective Agents Phase 3,Phase 2,Phase 1,Not Applicable
68 Folate Phase 3,Phase 2,Phase 1,Not Applicable
69 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Not Applicable
70 Vitamins Phase 3,Phase 1,Not Applicable
71 Antineoplastic Agents, Immunological Phase 3,Phase 2
72 Hematinics Phase 3
73 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
74 Micronutrients Phase 3,Phase 1,Not Applicable
75 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
76
asparaginase Phase 3,Phase 2,Not Applicable
77 HIV Protease Inhibitors Phase 3,Not Applicable
78 glucocorticoids Phase 3,Phase 2,Not Applicable
79 Methylprednisolone Acetate Phase 3,Phase 2
80 Folic Acid Antagonists Phase 3,Phase 2,Phase 1,Not Applicable
81 Antimitotic Agents Phase 3,Phase 2,Phase 1,Not Applicable
82 Autonomic Agents Phase 3,Phase 2,Not Applicable
83 Antirheumatic Agents Phase 3,Phase 2,Phase 1,Not Applicable
84 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1,Not Applicable
85 Dermatologic Agents Phase 3,Phase 2,Phase 1,Not Applicable
86 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2,Not Applicable
87 Antineoplastic Agents, Hormonal Phase 3,Phase 2,Not Applicable
88 Calcium, Dietary Phase 3,Phase 2,Phase 1,Not Applicable
89 Bone Density Conservation Agents Phase 3,Phase 1,Not Applicable
90 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1,Not Applicable
91 Antiemetics Phase 3,Phase 2,Not Applicable
92 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Not Applicable
93 Anti-Inflammatory Agents Phase 3,Phase 2,Not Applicable
94
protease inhibitors Phase 3,Not Applicable
95 Hormones Phase 3,Phase 2,Phase 1,Not Applicable
96 BB 1101 Phase 3,Not Applicable
97 Antiviral Agents Phase 3,Phase 2,Not Applicable
98 Alkylating Agents Phase 3,Phase 2,Phase 1,Not Applicable
99 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1,Not Applicable
100 Gastrointestinal Agents Phase 3,Phase 2,Not Applicable
101 Peripheral Nervous System Agents Phase 3,Phase 2,Not Applicable
102 Prednisolone acetate Phase 3,Phase 2
103 Anti-Infective Agents Phase 3,Phase 2,Not Applicable
104 Hormone Antagonists Phase 3,Phase 2,Not Applicable
105 Etoposide phosphate Phase 3,Phase 2,Phase 1,Not Applicable
106 Adjuvants, Immunologic Phase 3,Phase 2,Phase 1,Not Applicable
107 Analgesics Phase 3,Phase 2
108 Gemtuzumab Phase 3,Phase 2
109
Isophosphamide mustard Phase 3,Phase 2,Phase 1 0
110 Endothelin A Receptor Antagonists Phase 3
111 Endothelin Receptor Antagonists Phase 3
112 Estrogens Phase 3
113 Estrogen Receptor Antagonists Phase 3
114 Estrogen Antagonists Phase 3
115 Aromatase Inhibitors Phase 3
116 Steroid Synthesis Inhibitors Phase 3
117 Immunoglobulins Phase 3,Phase 2
118 Antibodies, Monoclonal Phase 3,Phase 2
119 Antibodies Phase 3,Phase 2
120 Photosensitizing Agents Phase 3
121 Dihematoporphyrin Ether Phase 3
122 Hematoporphyrin Derivative Phase 3
123 Ether Phase 3
124 Hematoporphyrins Phase 3
125 Albumin-Bound Paclitaxel Phase 3
126 Antioxidants Phase 3
127 Antibodies, Anti-Idiotypic Phase 3
128 cadexomer iodine Phase 3
129 Iodine-131 anti-B1 antibody Phase 3
130 Interferon-alpha Phase 3
131 Interferon alpha-2 Phase 3
132 interferons Phase 3
133
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
134
Amifostine Approved, Investigational Phase 2 20537-88-6 2141
135
Histamine Approved, Investigational Phase 2 51-45-6 774
136
Cyproheptadine Approved Phase 2 129-03-3 2913
137
Megestrol acetate Approved, Investigational, Vet_approved Phase 2 595-33-5 11683
138
Denileukin diftitox Approved, Investigational Phase 2 173146-27-5
139
Vinorelbine Approved, Investigational Phase 2 71486-22-1 44424639 60780
140
Gemcitabine Approved Phase 2 95058-81-4 60750
141
Busulfan Approved, Investigational Phase 2 55-98-1 2478
142
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
143
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662
144
Thiotepa Approved, Investigational Phase 2 52-24-4 5453
145
Hydrocortisone Approved, Vet_approved Phase 2,Not Applicable 50-23-7 5754
146
Hydrocortisone acetate Approved, Vet_approved Phase 2,Not Applicable 50-03-3
147
Topotecan Approved, Investigational Phase 1, Phase 2 119413-54-6, 123948-87-8 60700
148 Neuroprotective Agents Phase 2
149 acivicin Phase 2
150 Keratolytic Agents Phase 2
151 Podophyllotoxin Phase 2 518-28-5
152 Radiopharmaceuticals Phase 2
153 3-Iodobenzylguanidine Phase 2
154 Radiation-Protective Agents Phase 2
155 Central Nervous System Stimulants Phase 2
156 Histamine Antagonists Phase 2
157 Contraceptives, Oral Phase 2
158 Serotonin Agents Phase 2
159 Appetite Stimulants Phase 2
160 Contraceptive Agents Phase 2
161 Serotonin Antagonists Phase 2
162
Histamine Phosphate Phase 2 51-74-1 65513
163 Neurotransmitter Agents Phase 2
164 Anti-Allergic Agents Phase 2
165 Antipruritics Phase 2
166 Histamine H1 Antagonists Phase 2
167
Megestrol Phase 2 3562-63-8 3080587 19090
168 Analgesics, Non-Narcotic Phase 2
169 Interleukin-2 Phase 2
170 Antifungal Agents Phase 2
171 Calcineurin Inhibitors Phase 2
172 Cyclosporins Phase 2
173 Vinca Alkaloids Phase 2
174 Anti-Inflammatory Agents, Non-Steroidal Phase 2
175 Cyclooxygenase Inhibitors Phase 2
176 Cyclooxygenase 2 Inhibitors Phase 2
177 Hydrocortisone 17-butyrate 21-propionate Phase 2,Not Applicable
178 Hydrocortisone-17-butyrate Phase 2,Not Applicable
179 Hydrocortisone hemisuccinate Phase 2,Not Applicable
180
Serotonin Investigational, Nutraceutical Phase 2 50-67-9 5202
181
Zoledronic Acid Approved Phase 1 118072-93-8 68740
182
Imidazole Experimental, Investigational Phase 1 288-32-4 795
183 razoxane Phase 1
184 Cardiotonic Agents Phase 1
185
Bleomycin Approved, Investigational Not Applicable 11056-06-7 5360373
186
Bilirubin Not Applicable 635-65-4, 69853-43-6 21252250 5280352

Interventional clinical trials:

(showing 44, show less)
# Name Status NCT ID Phase Drugs
1 Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Unknown status NCT00265850 Phase 3 FOLFOX or;FOLFIRI
2 Combination Chemotx in Treating Children or Adolescents With Newly Diagnosed Stg III or Stg IV Lymphoblastic Lymphoma Unknown status NCT00004228 Phase 3 asparaginase;cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;doxorubicin hydrochloride;leucovorin calcium;mercaptopurine;methotrexate;prednisone;thioguanine;vincristine sulfate
3 Education With or Without Exercise and Counseling in Preventing Lymphedema in Women With Stage I, Stage II, or Stage III Breast Cancer Who Are Undergoing Axillary Lymph Node Dissection Completed NCT00376597 Phase 3
4 Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia Completed NCT00372593 Phase 3 asparaginase;cytarabine;daunorubicin hydrochloride;etoposide;gemtuzumab ozogamicin;mitoxantrone hydrochloride
5 High-Dose Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Metastatic Rhabdomyosarcoma or Ectomesenchymoma Completed NCT00354744 Phase 3 cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;irinotecan hydrochloride;vincristine sulfate
6 S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy Completed NCT00134056 Phase 3 atrasentan hydrochloride;docetaxel;prednisone
7 Radiation Therapy Compared With Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Primary Central Nervous System (CNS) Germ Cell Tumor Completed NCT00085098 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide
8 S0226 Anastrozole With or Without Fulvestrant as First-Line Therapy in Postmenopausal Women With Metastatic Breast Cancer Completed NCT00075764 Phase 3 anastrozole;fulvestrant
9 Dexamethasone Compared With Prednisone During Induction Therapy and MTX With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia Completed NCT00075725 Phase 3 cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;doxorubicin hydrochloride;leucovorin calcium;mercaptopurine;methotrexate;pegaspargase;prednisone;thioguanine;vincristine sulfate
10 Comparison of Two Combination Chemotherapy Regimens With Either Vincristine or Vinblastine in Treating Patients With Advanced Anaplastic Large Cell Lymphoma Completed NCT00059839 Phase 3 doxorubicin hydrochloride;mercaptopurine;methotrexate;prednisone;vinblastine sulfate;vincristine sulfate
11 Chemotherapy and Radiation Therapy After Surgery in Treating Patients With Stomach or Esophageal Cancer Completed NCT00052910 Phase 3 cisplatin;epirubicin hydrochloride;fluorouracil;leucovorin calcium
12 Combination Chemotherapy in Treating Children With Progressive Brain Tumors Completed NCT00002944 Phase 3 carboplatin;lomustine;procarbazine hydrochloride;thioguanine;vincristine sulfate
13 Clinical Study of Time Optimizing of Endoscopic Photodynamic Therapy on Esophageal and/or Gastric Cardiac Cancer Recruiting NCT02628665 Phase 3 photosensitizer(photofrin)
14 Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer Active, not recruiting NCT01302834 Phase 3 cisplatin
15 Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer Active, not recruiting NCT01107626 Phase 3 pemetrexed disodium
16 High-Dose or Standard-Dose Radiation Therapy and Chemotherapy With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery Active, not recruiting NCT00533949 Phase 3 Carboplatin;Paclitaxel
17 Selenium in Preventing Tumor Growth in Patients With Previously Resected Stage I Non-small Cell Lung Cancer Active, not recruiting NCT00008385 Phase 3 selenium
18 S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma Active, not recruiting NCT00006721 Phase 3 cyclophosphamide;doxorubicin;prednisone;vincristine
19 High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma Active, not recruiting NCT00003641 Phase 3
20 Early or Delayed Fludarabine and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia Terminated NCT00513747 Phase 3 fludarabine phosphate
21 Radiation Therapy in Treating Young Patients With Gliomas Unknown status NCT00238264 Phase 2
22 Radiation Therapy, Temozolomide, and Lomustine in Treating Young Patients With Newly Diagnosed Gliomas Unknown status NCT00100802 Phase 2 lomustine;temozolomide
23 Cyclophosphamide, Rituximab, and Either Prednisone or Methylprednisolone in Treating Patients With Lymphoproliferative Disease After Solid Organ Transplantation Unknown status NCT00066469 Phase 2 cyclophosphamide;methylprednisolone;prednisone
24 Observation or Radiation Therapy and/or Chemotherapy and Second Surgery in Treating Children Who Have Undergone Surgery for Ependymoma Unknown status NCT00027846 Phase 2 carboplatin;cyclophosphamide;etoposide;vincristine sulfate;Mesna
25 Irinotecan and Temozolomide in Treating Young Patients With Recurrent Neuroblastoma Completed NCT00311584 Phase 2 irinotecan hydrochloride;temozolomide
26 Amifostine in Treating Young Patients With Newly Diagnosed De Novo Myelodysplastic Syndromes Completed NCT00098683 Phase 2 amifostine trihydrate
27 Cyproheptadine and Megestrol in Preventing Weight Loss in Children With Cachexia Caused By Cancer or Cancer Treatment Completed NCT00066248 Phase 2 cyproheptadine hydrochloride;megestrol acetate
28 hu14.18-Interleukin-2 Fusion Protein in Treating Young Patients With Recurrent or Refractory Neuroblastoma Completed NCT00082758 Phase 2
29 Gemcitabine and Vinorelbine in Treating Young Patients With Recurrent or Refractory Hodgkin's Lymphoma Completed NCT00070304 Phase 2 gemcitabine hydrochloride;vinorelbine tartrate
30 Gemtuzumab Ozogamicin in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia Undergoing Remission Induction and Intensification Therapy Completed NCT00070174 Phase 2 asparaginase;busulfan;cyclophosphamide;cyclosporine;cytarabine;daunorubicin hydrochloride;etoposide;gemtuzumab ozogamicin;methotrexate;mitoxantrone hydrochloride
31 Inhaled Sargramostim in Treating Patients With First Pulmonary (Lung) Recurrence of Osteosarcoma Completed NCT00066365 Phase 2
32 Vinblastine, Celecoxib, and Combination Chemotherapy in Treating Patients With Newly-Diagnosed Metastatic Ewing's Sarcoma Family of Tumors Completed NCT00061893 Phase 2 celecoxib;cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;vinblastine sulfate;vincristine sulfate;MESNA;Filgrastim
33 Neoadjuvant Chemotherapy With or Without Second-Look Surgery Followed by Radiation Therapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Intracranial Germ Cell Tumors Completed NCT00047320 Phase 2 carboplatin;etoposide;ifosfamide;thiotepa
34 Combination Chemotherapy in Treating Children With Refractory or Relapsed Hodgkin's Lymphoma Completed NCT00006760 Phase 2 ifosfamide;vinorelbine tartrate
35 Induction Intensification in Treating Infants With Newly Diagnosed Acute Lymphoblastic Leukemia Completed NCT00002756 Phase 2 asparaginase;cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide;leucovorin calcium;mercaptopurine;methotrexate;prednisone;therapeutic hydrocortisone;vincristine sulfate
36 Topotecan, G-CSF, and Radiation Therapy in Treating Young Patients With Newly Diagnosed Brain Stem Glioma Terminated NCT00107471 Phase 1, Phase 2 topotecan hydrochloride
37 Surgery and/or Chemotherapy in Treating Children With Infantile, Congenital, or Childhood Fibrosarcoma Terminated NCT00072280 Phase 2 cyclophosphamide;etoposide;ifosfamide;vincristine sulfate
38 Zoledronic Acid and Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Osteosarcoma Completed NCT00742924 Phase 1 cisplatin;dexrazoxane hydrochloride;doxorubicin hydrochloride;etoposide;ifosfamide;leucovorin calcium;methotrexate;zoledronic acid;Mesna
39 Pharmacokinetics of Daunorubicin in Treating Young Patients With Cancer Unknown status NCT00673257 Not Applicable daunorubicin hydrochloride
40 Combination Chemotherapy and Radiation Therapy in Treating Patients With Acute Lymphoblastic Leukemia That Has Relapsed in the CNS or Testes Completed NCT00096135 Not Applicable cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;etoposide;leucovorin calcium;mercaptopurine;methotrexate;pegaspargase;therapeutic hydrocortisone;vincristine sulfate
41 Combination Chemotherapy in Treating Children With Newly Diagnosed Malignant Germ Cell Tumors Completed NCT00066482 Not Applicable cisplatin;cyclophosphamide;etoposide
42 informCLL™: A Disease Registry for Patients With Chronic Lymphocytic Leukemia Recruiting NCT02582879
43 Cancer Development In Organ Transplant Recipients Active, not recruiting NCT02333279
44 S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases Active, not recruiting NCT00874211

Search NIH Clinical Center for Heart Cancer

Cochrane evidence based reviews: heart neoplasms

Genetic Tests for Heart Cancer

Anatomical Context for Heart Cancer

MalaCards organs/tissues related to Heart Cancer:

42
Heart, Lung, Kidney, Bone, Brain, Breast, Myeloid

The Foundational Model of Anatomy Ontology organs/tissues related to Heart Cancer:

20
The Heart

Publications for Heart Cancer

Articles related to Heart Cancer:

(showing 14, show less)
# Title Authors Year
1
Heart cancer in the writings of the anatomo-clinical School members. ( 30358239 )
2018
2
Trade-offs in the effects of the apolipoprotein E polymorphism on risks of diseases of the heart, cancer, and neurodegenerative disorders: insights on mechanisms from the Long Life Family Study. ( 25482294 )
2015
3
AMP kinase: heart, cancer and the CNS--view from the chair. ( 18719594 )
2008
4
Priorities? Heart, cancer, child/maternal care. ( 1993533 )
1991
5
The role and contribution of epidemiology in planning, operation, and evaluation of Regional Medical Programs (heart, cancer, and stroke). I. Epidemiology and Regional Medical Programs. ( 5690222 )
1968
6
Heart--cancer--stroke; Indiana Regional Program. ( 5655146 )
1968
7
Regional program for heart, cancer and stroke. ( 6038911 )
1967
8
Northlands Regional Medical Program. Heart, Cancer and Stroke Law: Public Law 89-239. ( 6035375 )
1967
9
Comparison of two federal programs: PL 89-749, Comprehensive Health Planning, PL 89-239, Heart, Cancer, Stroke. ( 5342761 )
1967
10
The Regional Medical Program for Heart, Cancer and Stroke. ( 5006548 )
1967
11
Preview of heart, cancer and cerebrovascular disease control planning. ( 4227395 )
1966
12
Heart, Cancer, and Stroke: Bill Based on Presidential Commission Calls for Regional Medical Centers. ( 17751038 )
1965
13
New Health Act: AMA Criticism Reflected in Adoption of Bill on Heart, Cancer, and Stroke. ( 17742360 )
1965
14
Heart, Cancer, Stroke: Rising Opposition From Doctors May Slow Passage of Johnson Program. ( 17737381 )
1965